NYSE · Healthcare
Nuvation Bio Inc. (NUVB)
As-reported financials and recent SEC filings for Nuvation Bio Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$62.9M
Net income
$-204.6M
Net margin
—
Diluted EPS
$-0.60
ROE
-66.9%
P/E (TTM)
—
Market cap
—
Debt / equity
0.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0 | — | — |
| Gross profit | — | $795,000 | — | — | — |
| Operating income | $-213.1M | $-592.6M | $-99.8M | $-119.7M | $-93.3M |
| Net income | $-204.6M | $-567.9M | $-75.8M | $-104.2M | $-86.8M |
| Diluted EPS | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-06
View on EDGAR →8-K2026-06-30
View on EDGAR →424B52026-06-29
View on EDGAR →305B22026-06-29
View on EDGAR →FWP2026-06-26
View on EDGAR →424B52026-06-25
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →Largest Healthcare peers
Go deeper on NUVB
Search Nuvation Bio Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.